Author:
Abed A.,Beasley A.B.,Reid A.L.,Law N.,Calapre L.,Millward M.,Lo J.,Gray E.S.
Reference33 articles.
1. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial;Mok;Lancet,2019
2. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer;Paz-Ares;N Engl J Med,2018
3. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy;Havel;Nat Rev Cancer,2019
4. Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer;Lopez de Rodas;J Immunother Cancer,2022
5. Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy;Abed;J Immunother Cancer,2020